Teva Pharmaceutical Industries (TEVA) Current Deferred Tax Assets (2011 - 2016)

Teva Pharmaceutical Industries (TEVA) has reported Current Deferred Tax Assets for 6 consecutive years, with $801.0 million the latest figure, recorded in Q2 2016.

• For the quarter ending Q2 2016, Current Deferred Tax Assets fell 40.75% year-over-year to $801.0 million; the trailing twelve-month figure through Jun 2016 stood at $801.0 million (down 40.75% YoY), and the FY2015 full-year result was $735.0 million, down 25.98% from the prior year.
• Current Deferred Tax Assets held at $801.0 million in Q2 2016 per TEVA's latest filing, from $805.0 million in the prior quarter.
• Across five years, Current Deferred Tax Assets topped out at $1.4 billion in Q2 2015 and bottomed at $735.0 million in Q4 2015.
• Historically, Current Deferred Tax Assets has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2013.
• The sharpest annual moves came in 2015 and 2016: Current Deferred Tax Assets increased 26.83% in 2015, then tumbled 40.75% in 2016.
• Over 5 years, Current Deferred Tax Assets stood at $1.1 billion in 2012, then slipped by 5.08% to $1.1 billion in 2013, then fell by 8.39% to $993.0 million in 2014, then fell by 25.98% to $735.0 million in 2015, then increased by 8.98% to $801.0 million in 2016.
• According to Business Quant data, Current Deferred Tax Assets over the past three periods registered $801.0 million, $805.0 million, and $735.0 million for Q2 2016, Q1 2016, and Q4 2015 respectively.